Across TCGA pan-cancer cohorts, MIR5681A RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated MIR5681A data layer.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MIR5681A RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MIR5681A expression acts as an unfavorable survival marker.
OV are the cancer types where MIR5681A RNA most reproducibly stratifies survival.